Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Tony, Hans‐Peter; R Burmester, Gerd; Schulze‐Koops, Hendrik; Grünke, Mathias; Henes, J.; Kötter, Ina; Haas, Judith; Unger, L.; Lovric, Svjetlana; Haubitz, Marion; Fischer‐Betz, Rebecca; Chehab, Gamal; Rubbert‐Roth, Andrea; Specker, Christof; Weinerth, Jutta; U. Holle, Julia; Müller‐Ladner, Ulf; König, Ramona; Fiehn, Christoph; Burgwinkel, Philip; Budde, Klemens; Sörensen, H.; J. Meurer, Michael; Aringer, Martin; C. Kieseier, Bernd; Erfurt‐Berge, Cornelia; Sticherling, Michael; Veelken, Roland; Ziemann, Ulf; Strutz, Frank; von Wussow, Praxis; Meier, Florian; Hunzelmann, Nico; Schmidt, Enno; Bergner, Raoul; Schwarting, Andreas; Eming, Rüdiger; Hertl, Michael; Stadler, Rudolf; Schwarz-Eywill, Michael; Wassenberg, Siegfried; Fleck, Martin; Metzler, Claudia; K. Zettl, Uwe; Westphal, J.; Heitmann, Stefan; Laura Herzog, Anna; Wiendl, Heinz; Jakob, Waltraud; Schmidt, Elvira; Freivogel, Klaus; Dörner, Thomas; investigators, GRAID

doi:10.1186/ar3337

Public

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

Published in Arthritis Research & Therapy • May 13, 2011

Authors:

Hans‐Peter Tony

Gerd R Burmester

Hendrik Schulze‐Koops

Abstract

INTRODUCTION: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of...

Subject

Medicine

Rituximab

Rheumatology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!